BioCentury | May 21, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Reticulon 4 receptor (RTN4R; NgR) Studies in mice suggest that a soluble peptide fragment of NgR (sNgR)...
BioCentury | May 7, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Integrin a9 (ITGA9) Studies in cell culture and in rats suggest that upregulating ITGA9 could help treat...
BioCentury | Jan 29, 2007
Tools & Techniques

Little vascular plasters

...The move frees Trigen to pursue GPVI-related programs that it acquired from cardiovascular company ProCorde GmbH...
BioCentury | Jan 29, 2007
Company News

Millennium, Trigen Holdings AG deal

...syndrome this quarter. Trigen acquired the fusion protein that targets GPVI through its merger with ProCorde GmbH...
BioCentury | May 8, 2006
Finance

Europe’s Iceberg 2006

...which began as a U.K. company and became German via its 2005 merger with Procorde GmbH...
BioCentury | Oct 17, 2005
Finance

Ebb & Flow

...Trigen raised E26.5 million ($32.1 million) in its first round of funding since merging with ProCorde...
BioCentury | Oct 12, 2005
Financial News

Trigen raises EUR 26.5 million

...raised EUR 26.5 million ($32.1 million) in its first round of funding since merging with ProCorde...
BioCentury | Sep 19, 2005
Clinical News

ProCord: Phase I data

In an Israeli Phase I trial in 8 patients, ProCord was well tolerated with no evidence of neurological deterioration. Patients were enrolled in the study within 14 days of their injury and had a complete...
BioCentury | Jul 25, 2005
Strategy

Choosing to survive

...anticoagulation markets. Earlier this year, what was then Trigen Ltd. completed a merger with Germany's ProCorde GmbH...
BioCentury | Jul 25, 2005
Strategy

European takeouts

...C) U.K. $4.1M in stock for the 3% it didn't already own Apr Trigen U.K. ProCorde...
Items per page:
1 - 10 of 20
BioCentury | May 21, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Reticulon 4 receptor (RTN4R; NgR) Studies in mice suggest that a soluble peptide fragment of NgR (sNgR)...
BioCentury | May 7, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Integrin a9 (ITGA9) Studies in cell culture and in rats suggest that upregulating ITGA9 could help treat...
BioCentury | Jan 29, 2007
Tools & Techniques

Little vascular plasters

...The move frees Trigen to pursue GPVI-related programs that it acquired from cardiovascular company ProCorde GmbH...
BioCentury | Jan 29, 2007
Company News

Millennium, Trigen Holdings AG deal

...syndrome this quarter. Trigen acquired the fusion protein that targets GPVI through its merger with ProCorde GmbH...
BioCentury | May 8, 2006
Finance

Europe’s Iceberg 2006

...which began as a U.K. company and became German via its 2005 merger with Procorde GmbH...
BioCentury | Oct 17, 2005
Finance

Ebb & Flow

...Trigen raised E26.5 million ($32.1 million) in its first round of funding since merging with ProCorde...
BioCentury | Oct 12, 2005
Financial News

Trigen raises EUR 26.5 million

...raised EUR 26.5 million ($32.1 million) in its first round of funding since merging with ProCorde...
BioCentury | Sep 19, 2005
Clinical News

ProCord: Phase I data

In an Israeli Phase I trial in 8 patients, ProCord was well tolerated with no evidence of neurological deterioration. Patients were enrolled in the study within 14 days of their injury and had a complete...
BioCentury | Jul 25, 2005
Strategy

Choosing to survive

...anticoagulation markets. Earlier this year, what was then Trigen Ltd. completed a merger with Germany's ProCorde GmbH...
BioCentury | Jul 25, 2005
Strategy

European takeouts

...C) U.K. $4.1M in stock for the 3% it didn't already own Apr Trigen U.K. ProCorde...
Items per page:
1 - 10 of 20